FDA Flags Eye Safety Concerns as GSK Seeks Blenrep’s US Return

GSK; Blenrep; FDA; eye safety; ocular toxicity; advisory committee; multiple myeloma; drug approval; United States; relapsed/refractory multiple myeloma